(Q53050096)

10 May 2018

title

The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway. (English)

1 reference

10 May 2018

author

Brage Storstein Andresen

4

1 reference

10 May 2018

Annette Bakker

object named as

Annette Bakker

5

0 references

Anne Goriely

object named as

Anne Goriely

14

0 references

Bruce D. Gelb

0 references

Kim M Keppler-Noreuil

17

object named as

Kim M Keppler-Noreuil

1 reference

10 May 2018

15

Karen W Gripp

1 reference

10 May 2018

author name string

David A Stevenson

1

1 reference

10 May 2018

Lisa Schill

2

1 reference

10 May 2018

Lisa Schoyer

3

1 reference

10 May 2018

Pinar Bayrak-Toydemir

6

1 reference

10 May 2018

Emma Burkitt-Wright

7

1 reference

10 May 2018

Kathryn Chatfield

8

1 reference

10 May 2018

Florent Elefteriou

9

1 reference

10 May 2018

Ype Elgersma

10

1 reference

10 May 2018

Michael J Fisher

11

1 reference

10 May 2018

David Franz

12

1 reference

10 May 2018

Bruce D Gelb

13

1 reference

10 May 2018

Antonio Y Hardan

16

1 reference

10 May 2018

Bronwyn Kerr

18

1 reference

10 May 2018

Bruce Korf

19

1 reference

10 May 2018

Chiara Leoni

20

1 reference

10 May 2018

Frank McCormick

21

1 reference

10 May 2018

Scott R Plotkin

22

1 reference

10 May 2018

Katherine A Rauen

23

1 reference

10 May 2018

Karlyne Reilly

24

1 reference

10 May 2018

Amy Roberts

25

1 reference

10 May 2018

Abby Sandler

26

1 reference

10 May 2018

Dawn Siegel

27

1 reference

10 May 2018

Karin Walsh

28

1 reference

10 May 2018

Brigitte C Widemann

29

1 reference

10 May 2018

language of work or name

English

0 references

publication date

7 May 2016

1 reference

10 May 2018

American Journal of Medical Genetics

published in

1 reference

10 May 2018

volume

170

1 reference

10 May 2018

issue

8

1 reference

10 May 2018

page(s)

1959-1966

1 reference

10 May 2018

K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Cardiomyopathies in Noonan syndrome and the other RASopathies

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

KRAS as a Therapeutic Target

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Achieving consensus for clinical trials: the REiNS International Collaboration.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4945362

Cardiovascular disease in Noonan syndrome

13 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27155140

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/AJMG.A.37723

1 reference

10 May 2018

PMCID

4945362

1 reference

10 May 2018

PubMed ID

27155140

1 reference

10 May 2018